Latest News
Saturday November 29, 2008 — SchaeffersResearch
Drugmaker AstraZeneca (AZN) announced some disappointing news this morning when it said that its MedImmune unit has received a letter from the U.S. Food and Drug Administration (FDA) asking for additional information on motavizumab. The letter is in connection with the Biologics License Applicatio...
Wednesday November 26, 2008 — AstraZeneca
WILMINGTON, Del., Nov. 25 /PRNewswire-FirstCall/ -- AstraZeneca today announced it has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceuticals USA.The agreement settles the ...
Tuesday November 18, 2008 — AstraZeneca
WILMINGTON, Del., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca today announced the appointment of Rich Fante as President of the company's U.S. business.Fante takes over from Tony Zook, whose role was expanded after recently being named President of MedImmune, the wholly owned biologics busines...
Tuesday November 18, 2008 — MedImmune
GAITHERSBURG, Md., Nov. 17 /PRNewswire/ -- MedImmune today announced winners of a research abstract competition highlighting the work of tomorrow's potential scientific leaders in respiratory disease, inflammation and autoimmunity. Last Friday, MedImmune convened the competition's 10 finalists to...
Thursday November 13, 2008 — MedImmune
GAITHERSBURG, Md., Nov. 13 /PRNewswire/ -- MedImmune today announced the appointment of Tony Zook as its president. Previously, he had been heading the company on an interim basis.MedImmune is the wholly owned biologics business for AstraZeneca PLC. In addition to MedImmune, Mr. Zook is also resp...
Wednesday November 12, 2008 — AstraZeneca; Lung Cancer Alliance
WASHINGTON, Nov. 12 /PRNewswire-FirstCall/ -- Survey results released today show that the general population blames lung cancer patients for their diagnosis, confirming the stigma that patients reportedly feel. Findings also demonstrate a lack of public support for patients and a need for greate...
Sunday November 9, 2008 — AstraZeneca
NEW ORLEANS, Nov. 9 /PRNewswire-FirstCall/ -- New data from the JUPITER study demonstrated that CRESTOR(R) (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, ...
Monday November 3, 2008 — MedImmune
GAITHERSBURG, Md., Nov. 3 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most com...
Saturday November 1, 2008 — Zacks.com: Analyst Blog
AstraZeneca Plc (AZN) is facing a number of challenges, most notably from generic competition to Toprol-XL and Nexium. Management is determined to grow earnings through a combination of expanding the topline and cost cutting. This is in contrast to many of large-cap pharma companies, whic...
Thursday October 30, 2008 — AstraZeneca
WILMINGTON, Del., Oct. 29 /PRNewswire-FirstCall/ -- Data presented today from two pivotal efficacy and safety trials, SHINE and SUN, demonstrated that SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol significantly improved lung function and was well-tolerated in patients...
Friday October 24, 2008 — MedImmune
GAITHERSBURG, Md., Oct. 23 /PRNewswire/ -- MedImmune today announced that researchers will present eight posters from its inflammatory disease program at the Annual Meeting of the American College of Rheumatology, from October 24 to 29, 2008 at the Moscone Center in San Francisco, California."Med...
Thursday October 16, 2008 — MedImmune
GAITHERSBURG, Md., Oct. 16 /PRNewswire/ -- MedImmune announced today that it has licensed its proprietary reverse genetics intellectual property to Omninvest, a Hungarian research and manufacturing company, to support the development and construction of new vaccine strains to produce non-live hum...
Thursday October 16, 2008 — MedImmune
CAMBRIDGE, England, Oct. 16 /PRNewswire/ -- MedImmune today announced the opening of a new, biologics research and development (RD) facility in Cambridge, the United Kingdom. Named after the 1982 Nobel Prize Winner for Chemistry, the Aaron Klug Building is a major expansion of MedImmune's existi...
Wednesday October 15, 2008 — AstraZeneca
WILMINGTON, Del. and NEW YORK, Oct. 15 /PRNewswire-FirstCall/ -- AstraZeneca and Columbia University Medical Center today announced a new research collaboration to examine how neurogenesis -- the creation of new neuronal cells - in adults might offer novel approaches to treating depression and a...
Monday October 13, 2008 — MedImmune
BOSTON, Oct. 13 /PRNewswire-USNewswire/ -- Five neonatology fellows have been awarded grants designed to stimulate interest and research in the area of follow-up care of the premature infant as part of MedImmune's Fellowship Program. The grants, which underscore MedImmune's commitment to expandin...
Monday October 13, 2008 — AstraZeneca
WILMINGTON, Del., Oct. 13 /PRNewswire-FirstCall/ -- Affordability concerns and the perceived lack of need for a medicine are the top reasons why patients do not take their medicines as prescribed, according to a recent AstraZeneca survey of more than 200 office-based physicians.The physicians ra...
Friday October 10, 2008 — AstraZeneca
WILMINGTON, Del., Oct. 10 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR(R) (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disord...
Thursday October 9, 2008 — Zacks.com: Analyst Blog
AstraZeneca PLC (AZN) is engaged in the research, development, manufacturing and marketing of ethical (prescription) pharmaceutical products. The company ranks among the top pharmaceutical companies in the world based on revenues and global sales force. It is a leader in cardiovascular, c...
Tuesday October 7, 2008 — StockWeb
Global stock markets are still in the selling pressure and volatility index VIX is already second week above 40 points. In fact this week index is oscillating around level of 50. This is right time for value investor for bargain searching. Many worthy stocks are below P/E 10 with still perspective...
Tuesday September 30, 2008 — Hagens Berman Sobol Shapiro
BOSTON, Sept. 29 /PRNewswire/ -- Two major pharmaceutical companies are facing the fire this week after U.S. District Judge Patti Saris approved two national classes in the Average Wholesale Price litigation, allowing plaintiffs to pursue litigation against AstraZeneca and Bristol-Myers Squibb C...
Monday September 29, 2008 — MedImmune
GAITHERSBURG, Md., Sept. 29 /PRNewswire/ -- MedImmune announced today that it has licensed its proprietary reverse genetics intellectual property to BIKEN, The Research Foundation for Microbial Diseases of Osaka University in Japan to support the development and construction of new vaccine strain...
Wednesday September 24, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 23 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva's Motion for Summary Judgment of no infringement in the PULMICORT RESPULES(R) (budesonide inhalation suspension) patent litigation.The court a...
Wednesday September 24, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 23 /PRNewswire-FirstCall/ -- AstraZeneca , a global leader in the pharmaceutical industry, has been named one of the "100 Best Companies" to work for by Working Mother magazine for the seventh consecutive year. This honor recognizes the company's commitment to family-frien...
Tuesday September 23, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market CASODEX(R) (bicalutamide) for its licensed advanced prostate cancer indication until April...
Tuesday September 16, 2008 — AstraZeneca
WILMINGTON, Del., Sept. 15 /PRNewswire-FirstCall/ -- -- Results inconclusive, as primary outcome measure not statistically
significant for either donepezil or AZD3480; results impacted by
improvement in placebo group
-- Improvements shown on secondary outcome measures ADCS-CGIC and...